Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jun 28;15(7):1462.
doi: 10.3390/v15071462.

Modulation of the Host Response as a Therapeutic Strategy in Severe Lung Infections

Elyse Latreille  1   2 , Warren L Lee  1   2   3   4
Affiliations
Review

Modulation of the Host Response as a Therapeutic Strategy in Severe Lung Infections

Elyse Latreille et al. Viruses. .

Abstract

Respiratory pathogens such as influenza and SARS-CoV-2 can cause severe lung infections leading to acute respiratory distress syndrome (ARDS). The pathophysiology of ARDS includes an excessive host immune response, lung epithelial and endothelial cell death and loss of the epithelial and endothelial barrier integrity, culminating in pulmonary oedema and respiratory failure. Traditional approaches for the treatment of respiratory infections include drugs that exert direct anti-pathogen effects (e.g., antivirals). However, such agents are typically ineffective or insufficient after the development of ARDS. Modulation of the host response has emerged as a promising alternative therapeutic approach to mitigate damage to the host for the treatment of respiratory infections; in principle, this strategy should also be less susceptible to the development of pathogen resistance. In this review, we discuss different host-targeting strategies against pathogen-induced ARDS. Developing therapeutics that enhance the host response is a pathogen-agnostic approach that will help prepare for the next pandemic.

Keywords: endothelium; host response; inflammation; lung injury; lung regeneration; vascular stability.

PubMed Disclaimer

Conflict of interest statement

W.L.L. is a co-inventor of a patent for the use of Vasculotide for influenza and previously (2016–2018) served on the Scientific Advisory Board for Vasomune. E.L. declares no conflicts of interest.

Similar articles

See all similar articles

Cited by

References

    1. Smyk J.M., Szydłowska N., Szulc W., Majewska A. Evolution of influenza viruses—Drug resistance, treatment options, and prospects. Int. J. Mol. Sci. 2022;23:12244. doi: 10.3390/ijms232012244. - DOI - PMC - PubMed
    1. Latreille E., Lee W.L. Interactions of influenza and SARS-CoV-2 with the lung endothelium: Similarities, differences, and implications for therapy. Viruses. 2021;13:161. doi: 10.3390/v13020161. - DOI - PMC - PubMed
    1. Group T.R.C. Dexamethasone in hospitalized patients with COVID-19—Preliminary REPORT. N. Engl. J. Med. 2020;384:693–704. doi: 10.1056/NEJMoa2021436. - DOI - PMC - PubMed
    1. Calderaro A., Buttrini M., Farina B., Montecchini S., De Conto F., Chezzi C. Respiratory tract infections and laboratory diagnostic methods: A review with a focus on syndromic panel-based assays. Microorganisms. 2022;10:1856. doi: 10.3390/microorganisms10091856. - DOI - PMC - PubMed
    1. Clementi N., Ghosh S., De Santis M., Castelli M., Criscuolo E., Zanoni I., Clementi M. Viral respiratory pathogens and lung injury. Clin. Microbiol. Rev. 2021;34:e00103-20. doi: 10.1128/CMR.00103-20. - DOI - PMC - PubMed

Publication types

Grants and funding